Abstract
Five novel metalloproteinase protein inhibitors (MPIs) with molecular mass between 5.6 and 8.9 kDa and acid/neutral pI were detected in lupin seeds and exhibited strong inhibitory activities against thermolysin and/or gelatinase B. These novel peptides constitute not only the first MPIs described in plants but also the first plant peptides with inhibitory activity against a matrixin.
Keywords: Gelatinase B, lupin quiescent seed, matrixin peptide inhibitor, metalloproteinase protein inhibitor (MPI), thermolysin
Protein & Peptide Letters
Title: Discovery of Novel Plant Peptides as Strong Inhibitors of Metalloproteinases
Volume: 16 Issue: 5
Author(s): Dina M. Carrilho, Isabel C. Duarte, Rita Francisco, Candido P.P. Ricardo and Maria C. Duque-Magalhaes
Affiliation:
Keywords: Gelatinase B, lupin quiescent seed, matrixin peptide inhibitor, metalloproteinase protein inhibitor (MPI), thermolysin
Abstract: Five novel metalloproteinase protein inhibitors (MPIs) with molecular mass between 5.6 and 8.9 kDa and acid/neutral pI were detected in lupin seeds and exhibited strong inhibitory activities against thermolysin and/or gelatinase B. These novel peptides constitute not only the first MPIs described in plants but also the first plant peptides with inhibitory activity against a matrixin.
Export Options
About this article
Cite this article as:
Carrilho M. Dina, Duarte C. Isabel, Francisco Rita, Ricardo P.P. Candido and Duque-Magalhaes C. Maria, Discovery of Novel Plant Peptides as Strong Inhibitors of Metalloproteinases, Protein & Peptide Letters 2009; 16 (5) . https://dx.doi.org/10.2174/092986609788167789
DOI https://dx.doi.org/10.2174/092986609788167789 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Efficacy and Mechanism of Proteasome Inhibitors in Solid Tumor Treatment
Recent Patents on Anti-Cancer Drug Discovery Post-Docking Optimization and Analysis of Protein-Ligand Interactions of Estrogen Receptor Alpha using AMMOS Software
Current Computer-Aided Drug Design Imaging Features of Primary Tumors of the Hand
Current Medical Imaging Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation
Current Pharmaceutical Design AKT: A Potential Target for Thyroid Cancer Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Role of MMPs in Metastatic Dissemination: Implications for Therapeutic Advances
Current Pharmaceutical Biotechnology Molecular Predictors of Efficacy to Anti-EGFR Agents in Colorectal Cancer Patients
Current Cancer Drug Targets Angiogenesis Inhibition: State of the Art, Forgotten Strategies and New Perspectives in Cancer Therapy
Current Cancer Therapy Reviews Antiviral Medication in Sexually Transmitted Diseases. Part I: HSV, HPV
Mini-Reviews in Medicinal Chemistry Recent Advances in the Development of Catalytic Inhibitors of Human DNA Topoisomerase IIα As Novel Anticancer Agents
Current Medicinal Chemistry On the Epistemological Crisis in Genomics
Current Genomics Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Evaluation of Dendrimer Safety and Efficacy through Cell Line Studies
Current Drug Targets Dendrimer-drug Conjugates in Drug Delivery and Targeting
Pharmaceutical Nanotechnology The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting Angiogenesis in Renal Cell Carcinoma
Current Cancer Drug Targets Viral Vector-Mediated Gene Therapy for Hemophilia
Current Gene Therapy